Literature DB >> 22753418

Amino-terminal cysteine residues differentially influence RGS4 protein plasma membrane targeting, intracellular trafficking, and function.

Guillaume Bastin1, Kevin Singh, Kaveesh Dissanayake, Alexandra S Mighiu, Aliya Nurmohamed, Scott P Heximer.   

Abstract

Regulator of G-protein signaling (RGS) proteins are potent inhibitors of heterotrimeric G-protein signaling. RGS4 attenuates G-protein activity in several tissues. Previous work demonstrated that cysteine palmitoylation on residues in the amino-terminal (Cys-2 and Cys-12) and core domains (Cys-95) of RGS4 is important for protein stability, plasma membrane targeting, and GTPase activating function. To date Cys-2 has been the priority target for RGS4 regulation by palmitoylation based on its putative role in stabilizing the RGS4 protein. Here, we investigate differences in the contribution of Cys-2 and Cys-12 to the intracellular localization and function of RGS4. Inhibition of RGS4 palmitoylation with 2-bromopalmitate dramatically reduced its localization to the plasma membrane. Similarly, mutation of the RGS4 amphipathic helix (L23D) prevented membrane localization and its G(q) inhibitory function. Together, these data suggest that both RGS4 palmitoylation and the amphipathic helix domain are required for optimal plasma membrane targeting and function of RGS4. Mutation of Cys-12 decreased RGS4 membrane targeting to a similar extent as 2-bromopalmitate, resulting in complete loss of its G(q) inhibitory function. Mutation of Cys-2 did not impair plasma membrane targeting but did partially impair its function as a G(q) inhibitor. Comparison of the endosomal distribution pattern of wild type and mutant RGS4 proteins with TGN38 indicated that palmitoylation of these two cysteines contributes differentially to the intracellular trafficking of RGS4. These data show for the first time that Cys-2 and Cys-12 play markedly different roles in the regulation of RGS4 membrane localization, intracellular trafficking, and G(q) inhibitory function via mechanisms that are unrelated to RGS4 protein stabilization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753418      PMCID: PMC3436580          DOI: 10.1074/jbc.M112.345629

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  RGS4 is a negative regulator of insulin release from pancreatic beta-cells in vitro and in vivo.

Authors:  Inigo Ruiz de Azua; Marco Scarselli; Erica Rosemond; Dinesh Gautam; William Jou; Oksana Gavrilova; Philip J Ebert; Pat Levitt; Jürgen Wess
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

2.  Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin.

Authors:  Wenhua Liu; Eunice Y Yuen; Patrick B Allen; Jian Feng; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

3.  Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain.

Authors:  Izumi Sato; Yuuki Obata; Kousuke Kasahara; Yuji Nakayama; Yasunori Fukumoto; Takahito Yamasaki; Kazunari K Yokoyama; Takashi Saito; Naoto Yamaguchi
Journal:  J Cell Sci       Date:  2009-03-03       Impact factor: 5.285

4.  RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node.

Authors:  Carlo Cifelli; Robert A Rose; Hangjun Zhang; Julia Voigtlaender-Bolz; Steffen-Sebastian Bolz; Peter H Backx; Scott P Heximer
Journal:  Circ Res       Date:  2008-07-24       Impact factor: 17.367

5.  Unique hydrophobic extension of the RGS2 amphipathic helix domain imparts increased plasma membrane binding and function relative to other RGS R4/B subfamily members.

Authors:  Steven Gu; Janet He; Wing-Ting Ho; Suneela Ramineni; David M Thal; Ramanathan Natesh; John J G Tesmer; John R Hepler; Scott P Heximer
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

6.  Inhibition of Galphaq-dependent PLC-beta1 activity by PKG and PKA is mediated by phosphorylation of RGS4 and GRK2.

Authors:  Jiean Huang; Huiping Zhou; Sunila Mahavadi; Wimolpak Sriwai; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2006-08-02       Impact factor: 4.249

7.  Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures.

Authors:  Laura K K Pacey; Scott P Heximer; David R Hampson
Journal:  Mol Pharmacol       Date:  2009-04-07       Impact factor: 4.436

8.  Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.

Authors:  Yan Xie; Dennis W Wolff; Taotao Wei; Bo Wang; Caishu Deng; Joseph K Kirui; Haihong Jiang; Jianbing Qin; Peter W Abel; Yaping Tu
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Identification of G protein alpha subunit-palmitoylating enzyme.

Authors:  Ryouhei Tsutsumi; Yuko Fukata; Jun Noritake; Tsuyoshi Iwanaga; Franck Perez; Masaki Fukata
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

10.  Direct observation and quantitative analysis of Lck exchange between plasma membrane and cytosol in living T cells.

Authors:  Lars Zimmermann; Wolfgang Paster; Julian Weghuber; Paul Eckerstorfer; Hannes Stockinger; Gerhard J Schütz
Journal:  J Biol Chem       Date:  2009-12-29       Impact factor: 5.157

View more
  10 in total

Review 1.  The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21.

Authors:  B Sjögren
Journal:  Br J Pharmacol       Date:  2017-02-08       Impact factor: 8.739

Review 2.  Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.

Authors:  Katherine E Squires; Carolina Montañez-Miranda; Rushika R Pandya; Matthew P Torres; John R Hepler
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

3.  RGS4 Maintains Chronic Pain Symptoms in Rodent Models.

Authors:  Kleopatra Avrampou; Kerri D Pryce; Aarthi Ramakrishnan; Farhana Sakloth; Sevasti Gaspari; Randal A Serafini; Vasiliki Mitsi; Claire Polizu; Cole Swartz; Barbara Ligas; Abigail Richards; Li Shen; Fiona B Carr; Venetia Zachariou
Journal:  J Neurosci       Date:  2019-07-15       Impact factor: 6.167

4.  Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay.

Authors:  Andrew J Storaska; Jian P Mei; Meng Wu; Min Li; Susan M Wade; Levi L Blazer; Benita Sjögren; Corey R Hopkins; Craig W Lindsley; Zhihong Lin; Joseph J Babcock; Owen B McManus; Richard R Neubig
Journal:  Cell Signal       Date:  2013-09-14       Impact factor: 4.315

5.  Rab family proteins regulate the endosomal trafficking and function of RGS4.

Authors:  Guillaume Bastin; Scott P Heximer
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

6.  The dynamic role of regulator of G-protein signalling (RGS) proteins in partial agonism.

Authors:  Joobin Sattar; Kevin P Grace; Guillaume Bastin
Journal:  J Physiol       Date:  2014-09-01       Impact factor: 5.182

Review 7.  RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated signaling pathways in asthma.

Authors:  Nathalie Fuentes; Morgan McCullough; Reynold A Panettieri; Kirk M Druey
Journal:  Pharmacol Ther       Date:  2021-02-15       Impact factor: 13.400

Review 8.  Endomembrane-Based Signaling by GPCRs and G-Proteins.

Authors:  Federica Liccardo; Alberto Luini; Rosaria Di Martino
Journal:  Cells       Date:  2022-02-03       Impact factor: 6.600

9.  Gαi3-Dependent Inhibition of JNK Activity on Intracellular Membranes.

Authors:  Guillaume Bastin; Jin Ye Yang; Scott P Heximer
Journal:  Front Bioeng Biotechnol       Date:  2015-09-01

10.  RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents.

Authors:  I-Shan Chen; Kazuharu Furutani; Atsushi Inanobe; Yoshihisa Kurachi
Journal:  J Physiol       Date:  2014-01-13       Impact factor: 5.182

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.